Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Schizophr Res. 2013 Feb 21;146(0):190–195. doi: 10.1016/j.schres.2013.01.013

Table 3.

Outcome Measures of Effectiveness in the Efficacy Evaluable Population - by incoming study medication

Olanzapine
Quetiapine
Risperidone
Switch (N=29) Stay (N=35) Difference (95% CI) Switch (N=23) Stay (N=28) Difference (95% CI) Switch (N=37) Stay (N=35) Difference (95% CI)
Primary Outcome

 Change in Framingham Risk Score −0.020 ± 0.0055 −0.010 ± 0.0040 0.010 (−0.003,0.023) −0.024 ± 0.0062 −0.009 ± 0.0053 0.015 (−0.002,0.031) −0.014 ± 0.0042 −0.010 ± 0.0045 0.004 (−0.009,0.016)

Other Secondary Outcomes
 Metabolic Outcomes

  Change in weight (kg) −4.2 ± 0.88 −1.0 ± 0.73 3.2 (1.0,5.4) −2.2 ± 0.97 −0.6 ± 0.85 1.6 (−0.9,4.1) −4.0 ± 0.72 −0.8 ± 0.74 3.3 (1.2,5.3)

  Change in LDL Cholesterol (mg/dL) −26.1 ± 4.74 −15.2 ± 3.75 10.9 (−0.6,22.5) −10.7 ± 5.36 −13.3 ± 4.78 −2.6 (−16.4,11.2) −10.1 ± 3.85 −9.7 ± 4.12 0.4 (−10.3,11.1)

  Change in HDL Cholesterol (mg/dL) 0.9 ± 1.38 0.3 ± 1.08 −0.5 (−4.0,2.9) −0.4 ± 1.55 −0.1 ± 1.32 0.4 (−3.6,4.4) 1.1 ± 1.12 −0.7 ± 1.14 −1.8 (−4.9,1.4)

  Change in Triglycerides (mg/dL) −17.9 ± 14.43 −0.6 ± 11.38 17.3 (−18.6,53.3) −29.7 ± 16.49 12.6 ± 13.87 42.3 (0.5,84.0) −31.4 ± 11.66 7.3 ± 11.89 38.6 (6.1,71.2)

  Change in TG/HDL ratio −0.6 ± 0.45 −0.1 ± 0.35 0.5 (−0.6,1.6) −1.0 ± 0.51 0.4 ± 0.43 1.4 (0.1,2.7) −0.9 ± 0.36 0.2 ± 0.37 1.1 (0.1,2.1)

  Change in fasting glucose (mg/dL) 2.6 ± 2.58 4.5 ± 1.95 2.0 (−4.4,8.3) 1.6 ± 2.94 7.0 ± 2.44 5.4 (−2.0,12.8) −1.7 ± 2.05 1.1 ± 2.08 2.8 (−2.9,8.5)

  Waist circumference (inches) −1.6 ± 0.45 −0.8 ± 0.37 0.8 (−0.3,2.0) −0.8 ± 0.50 −0.4 ± 0.43 0.4 (−0.9,1.7) −1.5 ± 0.36 −0.2 ± 0.38 1.3 (0.3,2.3)

  Systolic blood pressure (mmHg) −2.7 ± 2.46 −4.0 ± 1.88 −1.2 (−7.2,4.7) −5.8 ± 2.76 −0.5 ± 2.30 5.2 (−1.6,12.1) −3.4 ± 1.94 0.7 ± 1.97 4.1 (−1.1,9.4)

  Diastolic blood pressure (mmHg) −4.5 ± 1.96 −3.1 ± 1.53 1.4 (−3.2,6.0) −3.2 ± 2.19 0.7 ± 1.84 3.8 (−1.4,9.1) −3.0 ± 1.57 −2.5 ± 1.60 0.5 (−3.6,4.5)
HHS Vulnerability Disclosure